This statistic depicts the total expenditure on health as a share of GDP (gross domestic product) in selected European countries in 2022. In that year, Switzerland spent the largest share of GDP on healthcare at ** percent, followed by Germany at **** percent.

In 2022, of the total healthcare expenditure of the 27 European Union countries, approximately ** percent went to inpatient curative and rehabilitative care, while ***** percent was spent on long-term care. Another ***** percent was spent on pharmaceuticals and other medical non-durable goods.

In 2023, the total healthcare expenditure per capita was approximately ******* U.S. dollars. Followed by Norway, which spent ******* U.S. dollars per capita.

This table describes the different types of income that the forms of financing for healthcare expenditure have. In this table, healthcare expenditure in current prices per type of financing (such as the Healthcare Insurance Act) is broken down into the different types of revenue, such as the income-related health insurance contribution. The classifications used are from the System of Health Accounts of Eurostat, Organisation for Economic Co-operation and Development (OECD) and the World Health Organisation (WHO; World Health Organization).

Data available from: 1998

Status of figures: The figures for 2022 and 2021 presented in the table are further provisional. The figures for the previous years are final. The total expenditure according to the forms of financing are equal to the total healthcare expenditure as shown in the table 'Healthcare expenditure; healthcare providers and funding' (see paragraph 3 for a link to this table).

Changes as of 23 May 2024: - Further provisional figures for 2021 and 2022 and final figures for 2020 have been published. - The term 'funding schemes' has been replaced by the term 'forms of funding' to better reflect the content of this selection.

When will there be new figures? Statistics on health care expenditure are currently being revised. New data sources are processed and the most up-to-date statistical insights are applied. Revised figures for 2021 and 2022 and provisional figures for 2023 will be published in Q4 2024. Revised figures for 1998-2020 will be published in 2025.
The figures on total expenditure according to the forms of financing are also adjusted at those times, so that they remain in line with the most recent figures on expenditure on care (after revision).

In 2023, the United States had the highest per capita health expenditure among OECD countries. At that time, per capita health expenditure in the U.S. amounted over ****** U.S. dollars, significantly higher than in Switzerland, the country with the second-highest per capita health expenditure. Norway, Germany and Austria are also within the top five countries with the highest per capita health expenditure. The United States also spent the highest share of it’s gross domestic product on health care, with **** percent of its GDP spent on health care services. Health Expenditure in the U.S. The United States is the highest spending country worldwide when it comes to health care. In 2022, total health expenditure in the U.S. exceeded **** trillion dollars. Expenditure as a percentage of GDP is projected to increase to approximately ** percent by the year 2031. Distribution of Health Expenditure in the U.S. Health expenditure in the United States is spread out across multiple categories such as nursing home facilities, home health care, and prescription drugs. As of 2022, the majority of health expenditure in the United States was spent on hospital care, accounting for a bit less than *** third of all health spending. Hospital care was followed by spending on physician and clinical services which accounted for ** percent of overall health expenditure.

This table contains the expenditure on health care used by residents of the Netherlands in a year. Healthcare is defined according to the international definition of the System of Health Accounts. The figures are therefore internationally comparable with publications by Eurostat, OECD and WHO. All healthcare activities count, regardless of whether they take place within or outside the healthcare sector. The figures are derived from the Care Accounts, which includes more activities, such as youth care, welfare work, social services and childcare. The health accounts also include exports (expenditure for and by non-residents), included in the table as financing from abroad. The table also shows how the total figure on health care expenditure according to the Health Care Accounts is arrived at to the international total figure: Total health care expenditure according to the Health Care Accounts -/- exports -/- expenditure on welfare, child care for residents -/- expenditure on health-related products such as household care in elderly care, for residents = Total current expenditure on health care Data available from 1998 to 2022 Status of the figures: The figures for 2022 are provisional; the figures for 2020 and 2021 are more provisional; the other figures are final. Since this table has been discontinued, the figures for 2020-2022 are no longer finalized. Changes as of July 7, 2023: - The figures for 2022 have been added, the figures for 2019-2021 have been adjusted. - The table has been discontinued. When will new numbers come out? None, this table has been discontinued and will be replaced by 3 new tables, see section 3.

This table contains information on expenditure and financing in current prices on the health care used by residents in the Netherlands in one year. All activities within the area of health care are included, irrespective of whether they are performed within or outside the health care sector. These figures are based on the definition of the System of Health Accounts as used by EUROSTAT, the OECD and the WHO. The figures are derived from the Dutch statistics on health and social care, which cover a broader range of activities (including e.g. child day care, welfare, and social services). Exports are also included. In this table it can be found in the financing item Rest of the world; exports.

This table also shows how the total figure in accordance with the System of Health Accounts is calculated from the total figure health and social care:

Total figure on health and social care -/- exports -/- non-healthcare providers (welfare, children’s day care) for residents -/- health-related products (like social long term care) for residents = Total current expenditure on health

Data available from 1998 to 2022

Status of the figures: The figures for 2022 are provisional; the figures for 2020-2021 are revised provisional; the figures for the other years are final. The figures for 2020-2022 will not be made final, as this table has been discontinued.

Changes as of 14 July 2023: - The figures for 2022 have been added, the figures for 2019-2021 have been updated. - The table has been discontinued.

When will new figures be published? Not, this table has been discontinued and will be replaced by new tables, see section 3.

This table shows how health(care) expenditure according to the international definition and health and social care expenditure used by Statistics Netherlands are related. Financing has been chosen as the starting point. Healthcare is delineated according to the international definition of the System of Health Accounts. All healthcare activities count, regardless of whether they take place inside or outside the healthcare sector. Only resident health expenditure counts. Health and social care expenditure covers all care activities, including welfare and childcare, regardless of whether these activities take place as a main or secondary activity. Care can be for residents or non-residents. Care provided in the Netherlands for non-residents (such as tourists) is included in the export of services.

In brief: Health and social care expenditure -/- health-related expenditure, such as domestic care within care for the elderly -/- expenditure on other care and welfare, such as childcare -/- expenditure on education, research and development, other services -/- export, foreign-paid activities = Total current expenditure on health

Data available from 1998 to 2022

Status of the figures: The figures for 2021 and 2022 are revised provisional. The figures for the other years are final. Since this table has been discontinued, provisional data will not become final.

Changes as of 10 December 2024: This table has been discontinued. The name of the topic 'Care expenditure' has been changed to 'Health and social care expenditure'.

When will new figures be published? Not applicable anymore. The table has been discontinued and superseded by table 'Health expenditure: national and international figures compared; providers' (see paragraph 3). The new table contains revised data. New sources and statistical techniques have been incorporated in the revised figures.

Over the period from 2005 to 2023, health expenditure as share of GDP in Italy fluctuated between *** percent and *** percent. More specifically, it increased between 2005 and 2009, before gradually decreasing. In 2020, the total healthcare expenditure (public, private, and out-of-pocket) peaked at *** percent of the country's gross domestic product, also as a result of the country's response to the COVID-19 pandemic. In 2023, the total health expenditure as a share of GDP in Italy was *** percent.    European framework The Italian share was lower the European average, which was equal to **** percent in 2020. Moreover, some of the major European economies such as France and Germany, addressed a much higher share of the GDP to healthcare. As a matter of fact, in 2023, France and Germany spent **** and **** percent of their GDP on health respectively. Private healthcare spending In the last few years, conversely with the decrease of public healthcare resources, the private spending on health increased. The private health expenditure peaked at **** billion euros in 2022. Specialist examinations and dental checks were the most burdening headings for Italians in terms of private healthcare costs.

Analysis of ‘SHA05 - Current Health Care Expenditure’ provided by Analyst-2 (analyst-2.ai), based on source dataset retrieved from http://data.europa.eu/88u/dataset/92c2966e-29d9-44bd-afa5-5b06e7b8a47a on 16 January 2022.

--- Dataset description provided by original source is as follows ---

Current Health Care Expenditure

--- Original source retains full ownership of the source dataset ---

The European healthcare big data analytics market is experiencing robust growth, driven by the increasing volume of healthcare data generated through electronic health records (EHRs), wearable devices, and other digital health technologies. This surge in data necessitates advanced analytics capabilities to improve patient care, optimize operational efficiency, and accelerate drug discovery. The market's Compound Annual Growth Rate (CAGR) of 19% from 2019 to 2024 signifies significant market expansion, projected to continue into the forecast period (2025-2033). Key drivers include the rising prevalence of chronic diseases demanding personalized medicine, stringent regulatory requirements for data security and interoperability, and government initiatives promoting digital health transformation across Europe. The market is segmented by technology type (predictive, prescriptive, and descriptive analytics), application (clinical, financial, and operational), product (hardware, software, and services), delivery mode (on-premise and cloud-based), and end-user (healthcare providers, pharmaceutical and biotechnology companies, and academic organizations). The strong presence of major players like IBM, Oracle, Cerner, and McKesson indicates a competitive yet rapidly evolving landscape. Growth is particularly strong in countries like the UK, Germany, and France, reflecting higher healthcare expenditure and technological adoption rates. However, challenges remain, including data privacy concerns, the need for robust cybersecurity infrastructure, and the integration of legacy systems with new data analytics platforms. Overcoming these hurdles is key to unlocking the full potential of big data analytics in improving healthcare outcomes across Europe. The projected market value for 2025 serves as a strong baseline for forecasting future growth. Considering the 19% CAGR and the inherent growth potential in the healthcare sector, a sustained, albeit slightly moderated, growth rate is anticipated for the coming years. The market is expected to see continued investment in cloud-based solutions, driven by their scalability, cost-effectiveness, and accessibility. The focus on predictive analytics will likely increase, aiming to anticipate patient needs and optimize resource allocation. Furthermore, the integration of artificial intelligence (AI) and machine learning (ML) within big data analytics platforms is poised to accelerate innovation and further propel market growth. The ongoing emphasis on interoperability across healthcare systems will stimulate demand for integrated data analytics solutions, leading to greater efficiency and improved data-driven decision making. This continued growth will solidify Europe's position as a key player in the global healthcare big data analytics market. Recent developments include: May 2022 : The European Health Data Space was introduced by the European Commission (EHDS). The EHDS should assist the EU in significantly improving how healthcare is supplied to people throughout Europe. People should be able to manage and use their health information in their nation or another Member State. It should promote a single market for services and goods related to digital health. Additionally, it should guarantee complete adherence to the stringent data protection requirements set by the EU and provide a consistent, reliable, and effective framework for using health data for research, innovation, policy-making, and regulatory activities., November 2022 : The largest health services provider in Israel, Clalit, and IQVIA, a leading global provider of advanced analytics, technological solutions, and clinical research services to the life sciences sector, have announced a long-term partnership. The partnership assures IQVIA it can meet the pharmaceutical industry's interest in Israel as a top location for research and innovation by combining Clalit's aim to improve policy and healthcare with IQVIA's Connected Intelligence.. Key drivers for this market are: Reduced Cost of Care and Prediction of Possible Emergency Services, Increasing Evidence-based Activities and Shift from Volume- to Value-based Commissioning. Potential restraints include: Reduced Cost of Care and Prediction of Possible Emergency Services, Increasing Evidence-based Activities and Shift from Volume- to Value-based Commissioning. Notable trends are: Clinical Data Analytics to Witness Significant Growth Over the Forecast Period.

Analysis of ‘SHA01 - Current Health Care Expenditure’ provided by Analyst-2 (analyst-2.ai), based on source dataset retrieved from http://data.europa.eu/88u/dataset/7a424831-05d7-4129-98ef-b90937186495 on 18 January 2022.

--- Dataset description provided by original source is as follows ---

Current Health Care Expenditure

--- Original source retains full ownership of the source dataset ---

Analysis of ‘SHA02 - Current Health Care Expenditure’ provided by Analyst-2 (analyst-2.ai), based on source dataset retrieved from http://data.europa.eu/88u/dataset/89ed553c-9661-4f0f-bfea-ae348803acc2 on 14 January 2022.

--- Dataset description provided by original source is as follows ---

Current Health Care Expenditure

--- Original source retains full ownership of the source dataset ---

Health care spending in Turkey as a share of the gross domestic product (GDP) amounted to **** percent in 2022, which was the lowest figure recorded throughout the observed period. In the years 2007 to 2009, health care spending peaked at *** percent of GDP in Turkey but has fallen since then.

Health expenditure compared to Europe 

In comparison to other European countries in 2022, Turkey was at the bottom of the ranking in terms of health care spending as a share of the GDP. Top of the list was Germany, which spent **** percent of its’ GDP on health care in this year. While France and the United Kingdom both spent about ** percent on health. 

Interactions with the health system in Turkey

In 2022, roughly *** in ten individuals had visited a general practitioner in the past 12 months, women were more likely than men to do so. Furthermore, a 2023 study found that ** percent of those surveyed rated the quality of health care in Turkey as good, compared to ** percent who rated it as poor. 

According to Cognitive Market Research, the Cardiovascular Devices Market Size will be USD XX Billion in 2024 and is set to achieve a market size of USD XX Billion by the end of 2033 growing at a CAGR of XX% from 2025 to 2033.

• North America held largest share of XX% in the year 2024 • Europe held share of XX% in the year 2024 • Asia-Pacific held significant share of XX% in the year 2024 • South America held significant share of XX% in the year 2024 • Middle East and Africa held significant share of XX% in the year 2024

Market Dynamics of the Cardiovascular Devices Market Key Drivers for the Cardiovascular Devices Market

Rising in cardiovascular diseases prevalence fuels the cardiovascular devices market 

The cardiovascular disorders are the group of medical condition where it affects heart and blood vessels, encompassing various diseases and disorder that affects on the circulatory system. The cardiac devices help to maintain the regular heart function and blood flow in patients with weak improper function of heart. The global cardiac device market shows significant growth, largely driven by increase in prevalence of heart disease. The cardiovascular disease treatment is costly in terms of healthcare services. Now the conditions like coronary artery disease and heart failure are becoming increasingly prevalent, so there is increase in demand of coronary stents and crucial devices which are used to treat the cardiovascular diseases. Also, the global population increases and continues to age the incidence of chronic heart condition is expected to rise. This demographic condition is shift further and results in growing need of cardiovascular devices that can treat the wide range of heart diseases. For instance, according to centers for disease control and prevention (CDC) in the United States heart diseases is the major cause of death for both men and women and people of most racial and ethnic groups. They said that one person dies every 33 seconds from cardiovascular disease. In 2022, 702,880 people died from heart disease. That is equivalent to 1 in every 5 deaths (Source - https://www.cdc.gov/heart-disease/index.html ) Thus, due to the rising patients in cardiovascular disease segment and the advancement in technology boosts the cardiovascular devices market. Rising awareness of health also helps to drive this market.

The rise in healthcare expenditure drives the Cardiovascular Devices Market

Globally the health awareness is increasing vastly countries monitor their health of the population related to cardiac health preferably. They also focus on the expansion of healthcare expenditure where the people also now get aware about their health. The advancement in technology of medical devices increases the patient convenience and now they can get treatment and monitor their health more effectively. Each country now spends on their healthcare expenditure to provide healthcare service to all needy people who cannot afford the costly devices. For instance, U.S. health expenditure grew by 4.1% in 2022 to $4.5 trillion or $13,493 per capita. This rate of growth is similar to pre-pandemic levels (4.1% in 2019). While government expenditure to contain the pandemic resulted in significant growth in NHE, these expenditures fell sharply in 2021 while use of medical goods and services recovered. By 2022, overall trends in health expenditure more closely approximated that of the pre-pandemic era. (Source - https://www.ama-assn.org/about/research/trends-health-care-spending ) The market for cardiovascular devices is expected to grow as a result of rising healthcare costs. The total amount spent on healthcare-related services, goods, and activities over a given time period usually at the individual, community, national, or international level is referred to as healthcare expenditures. Adoption of cutting-edge cardiovascular technologies and devices is made possible by increased healthcare spending, which improves patient outcomes and care. For Instance, in Europe the spending on cardiovascular disease is greater than the spending done in Germany. CVD is estimated to cost the EU €282 billion annually, with health and long-term care accounting for €155 billion (55%), equaling 11% of EU-health exp...

The public and private per capita health expenditure differs significantly by country. As of 2023, the United States had by far the highest public per capita spending worldwide. Moreover, the U.S. had the second-highest private expenditure on health globally just after Switzerland. Health expenditures globally Health expenditures include the consumption of health goods, services and public health programs as well as insurance and government spending. Globally, health expenditures are on the rise. Among all countries the average per capita health expenditure is projected to see an increase of over 30 percent from the 2019 totals by the year 2050. Despite the growing expenditures, there are still countries with relatively low health expenditures. The countries with the lowest governmental health expenditure include South Sudan, Eritrea and Bangladesh. Health expenditures spotlight: the U.S. In 2021 the U.S. national health expenditure was at an all-time high. However, the projections indicate that total health expenditures will increase even more. The per capita health expenditures for the U.S. looked equally grim, with 2021 projected to be the most expensive year for health care on record. Despite having seen a significant increase in the total cost of health care in the U.S., trends indicate that the annual percentage change in health expenditures is decreasing over time.

The European healthcare big data analytics market is experiencing robust growth, driven by the increasing volume of patient data generated from electronic health records (EHRs), wearables, and other connected health devices. A compound annual growth rate (CAGR) of 19% from 2019 to 2024 suggests a significant market expansion, and this momentum is projected to continue through 2033. Key drivers include the rising prevalence of chronic diseases necessitating improved disease management, the increasing demand for personalized medicine, and government initiatives promoting the adoption of digital health technologies across Europe. The market is segmented by technology type (predictive, prescriptive, and descriptive analytics), application (clinical, financial, and operational data analytics), product (hardware, software, and services), mode of delivery (on-premise and cloud-based), and end-user (healthcare providers, pharmaceutical companies, biotechnology firms, and academic organizations). The strong presence of major players like SAS Institute, IBM, and McKesson underscores the market's maturity and competitive landscape. Specific regional growth within Europe will likely be influenced by factors such as national healthcare policies, digital infrastructure development, and data privacy regulations, with countries like the United Kingdom, Germany, and France expected to lead the market due to their advanced healthcare systems and substantial investments in digital health initiatives. The cloud-based model is expected to dominate the market due to its scalability, cost-effectiveness, and accessibility. Predictive analytics, enabling proactive interventions and risk stratification, is gaining significant traction, particularly within the clinical data analytics segment. However, challenges such as data interoperability issues, concerns around data security and privacy (GDPR compliance being particularly relevant in Europe), and the high cost of implementation could potentially restrain market growth. Nevertheless, the overall outlook for the European healthcare big data analytics market remains positive, promising substantial opportunities for technology providers and healthcare organizations alike to improve patient care, optimize operational efficiency, and drive innovation in healthcare delivery. The market’s size in 2025 is estimated at €X billion (a figure readily obtainable through market research databases given the specified CAGR and available historical data), providing a strong base for future growth projections. This report provides a detailed analysis of the burgeoning Europe healthcare big data analytics market, projecting its growth from 2019 to 2033. With a base year of 2025 and an estimated market value of XXX million, this study offers invaluable insights for stakeholders across the healthcare ecosystem. We delve into market segmentation, competitive landscape, and key trends shaping this dynamic sector, empowering businesses to make informed strategic decisions. The report covers the period from 2019 to 2024 (historical period), with a forecast period spanning 2025 to 2033. Recent developments include: May 2022 : The European Health Data Space was introduced by the European Commission (EHDS). The EHDS should assist the EU in significantly improving how healthcare is supplied to people throughout Europe. People should be able to manage and use their health information in their nation or another Member State. It should promote a single market for services and goods related to digital health. Additionally, it should guarantee complete adherence to the stringent data protection requirements set by the EU and provide a consistent, reliable, and effective framework for using health data for research, innovation, policy-making, and regulatory activities., November 2022 : The largest health services provider in Israel, Clalit, and IQVIA, a leading global provider of advanced analytics, technological solutions, and clinical research services to the life sciences sector, have announced a long-term partnership. The partnership assures IQVIA it can meet the pharmaceutical industry's interest in Israel as a top location for research and innovation by combining Clalit's aim to improve policy and healthcare with IQVIA's Connected Intelligence.. Key drivers for this market are: Reduced Cost of Care and Prediction of Possible Emergency Services, Increasing Evidence-based Activities and Shift from Volume- to Value-based Commissioning. Potential restraints include: Maintaining the Privacy and Integrity of Patient Data. Notable trends are: Clinical Data Analytics to Witness Significant Growth Over the Forecast Period.

The Healthcare IT Provider market is experiencing robust growth, projected to reach a substantial value by 2033, driven by a 13.50% CAGR from 2025. This expansion is fueled by several key factors. The increasing adoption of electronic health records (EHRs) and other digital health solutions is streamlining healthcare operations, improving patient care, and reducing costs. Furthermore, the rise of telehealth and remote patient monitoring is expanding access to healthcare, particularly in underserved areas, significantly boosting demand for supporting IT infrastructure. Governments worldwide are also investing heavily in digital healthcare initiatives, further propelling market growth. The market is segmented across various business segments, including Laboratory Information Systems (LIS), Radiology Information Systems (RIS), and Electronic Health Records (EHR), with each segment contributing significantly to the overall market value. The diverse range of components (software, hardware, services) and delivery modes (on-premise, cloud-based) offers flexibility to healthcare providers of all sizes. Major players such as Allscripts, Cerner, GE Healthcare, and Epic Systems are shaping market competition through continuous innovation and strategic acquisitions. Despite the significant growth potential, certain challenges persist. High initial investment costs for implementing and maintaining healthcare IT systems can be a barrier for smaller healthcare providers, particularly in developing regions. Data security and privacy concerns continue to be paramount, requiring robust cybersecurity measures. The complexity of integrating various healthcare IT systems also poses an ongoing challenge. However, the long-term benefits of improved efficiency, enhanced patient care, and reduced operational costs are outweighing these challenges, contributing to the sustained growth of the market. The market's regional distribution shows a strong presence in North America and Europe, though growth in the Asia Pacific region is accelerating due to increasing healthcare expenditure and technological advancements. Recent developments include: December 2022: Charles River Community Health (CRCH) transitioned to the Epic Electronic Health Records (EHR) system. Epic will likely provide patients with improved care and access to a new online patient portal., November 2022: HCA Healthcare signed a new agreement for a large-scale deployment of the MEDITECH Expanse clinical decision support tool. This expanse will likely provide HCA Healthcare clinicians with an intuitive, mobile user interface personalized to their unique workflows. Embedded clinical decision support and advanced solutions, such as Surveillance, are expected to advance their mission to provide exceptional care at the bedside and beyond. This agreement identifies MEDITECH Expanse as HCA Healthcare's primary go-forward EHR platform and a key part of the company's digital transformation.. Key drivers for this market are: Rise in the Demand for Paper-less Technology, Emergence of Social Media and its Impact on the Healthcare IT Industry; Increased Government Funding on Healthcare Services and Infrastructure. Potential restraints include: Rise in the Demand for Paper-less Technology, Emergence of Social Media and its Impact on the Healthcare IT Industry; Increased Government Funding on Healthcare Services and Infrastructure. Notable trends are: Clinical Decision Support System (CDSS) Segment Expected to Drive the Market.

The European mHealth market, valued at €27.61 billion in 2025, is experiencing robust growth, projected to expand at a compound annual growth rate (CAGR) of 25.43% from 2025 to 2033. This significant expansion is driven by several key factors. The increasing prevalence of chronic diseases like diabetes and cardiovascular conditions necessitates remote patient monitoring and telehealth solutions, fueling demand for mHealth services. Furthermore, the rising adoption of smartphones and wearable technology provides convenient access to health information and management tools. Government initiatives promoting digital healthcare and the growing focus on cost-effective healthcare delivery are also contributing to market growth. Stronger regulations and data privacy concerns might present challenges, but the overall market trajectory remains positive. Segmentation reveals that remote patient monitoring services are a major growth driver within the service type category, while blood glucose monitors and cardiac monitors dominate the device type segment. Major players like Medtronic, Philips, and Johnson & Johnson are leveraging technological advancements to enhance their offerings and compete in this rapidly evolving landscape. Market penetration within the various European nations will vary, with countries like Germany, the UK, and France likely leading the adoption due to advanced healthcare infrastructure and higher per capita healthcare spending. The continued innovation in areas such as AI-powered diagnostics and personalized medicine will further accelerate market expansion in the forecast period. The European mHealth market’s diverse stakeholder landscape includes mobile operators, healthcare providers, and application/content players. Each stakeholder plays a vital role in shaping market growth. Mobile operators provide the necessary network infrastructure, while healthcare providers integrate mHealth solutions into their existing care models. Application/content players develop innovative apps and software solutions that cater to specific healthcare needs. The competitive landscape is dynamic, with established medical device companies and technology giants vying for market share. The future of the European mHealth market hinges on continued technological innovation, regulatory clarity, and the successful integration of mHealth solutions into mainstream healthcare delivery. Effective cybersecurity measures and patient data protection will be paramount for sustained market growth and public trust. Recent developments include: In July 2022, Smith+Nephew launched the WOUND COMPASS Clinical Support App in the United Kingdom. The WOUND COMPASS Clinical Support App is a comprehensive digital support tool for health care professionals that aids wound assessment and decision-making to help reduce practice variation., In May 2022, digital mental health company, Bezyl, Inc. is collaborating with Ukrainian-based developer, Sigma Software to launch the Bezyl app, which builds mental strength and provides resources for assistance.. Key drivers for this market are: Rise in Use of Smartphones, Tablets, Increasing Focus on Personalized Medicine and Patient-Centered Approach; Increased Need of Point of Care Diagnosis and Treatment. Potential restraints include: Rise in Use of Smartphones, Tablets, Increasing Focus on Personalized Medicine and Patient-Centered Approach; Increased Need of Point of Care Diagnosis and Treatment. Notable trends are: Blood Glucose Monitors are Expected to Have the Largest Share in Device Type Segment.

Analysis of ‘Issuance of Cost Information ’ provided by Analyst-2 (analyst-2.ai), based on source dataset retrieved from http://data.europa.eu/88u/dataset/5b03f6fac8d8c9229f4afa55 on 12 January 2022.

--- Dataset description provided by original source is as follows ---

Monitor the volume of cost information issued in hospital institutions (in the areas of urgency and external consultation) in order to promote cost transparency and information sharing.

The objective of this information is to raise citizens’ awareness of the national economic effort, thus promoting the most appropriate use of hospital care, in order to ensure optimal and efficient use of available resources and to continue to guarantee the right to health protection, the realisation of which results in a joint responsibility of citizens, society and the State.

The information on health care costs comes within the framework of the XIX Constitutional Government Program and, in addition, the set of recommendations that incorporate the initiatives proposed by the Technical Group for Hospital Reform (GTRH), created by Order No 10601/2011 of August 16, where the importance of informing citizens of their rights is highlighted.

As such, it was determined that the institutions should make available the information on costs incurred with all health services provided to the user, borne by the State, according to the SNS price list. The information of costs incurred made available is of a purely informative nature, being duly explained to the user that it does not imply any additional payment.

Remarks: The values of the Hospital and University Center of Coimbra, EPE contain the sum of the cost information issued in all the centers of the Hospital Center (with and without SONHO system).

--- Original source retains full ownership of the source dataset ---